GENSCRIPT BIO(01548): Legend announces report published at the 2025 ASH Annual Meeting.

GENSCRIPT BIO (01548) announced that Legend Biotech Corporation ("Legend"), a joint venture company of the Company, whose shares are listed on the NASDAQ Global Select Market in the form of American depositary shares, announced in a press release on December 6, 2025 (New York time) that at the 2025 American Society of Hematology ("ASH") Annual Meeting, it presented clinical and translational research data from the long-term follow-up studies of the CARTITUDE-1 and CARTITUDE-4 trials for CARVYKTI (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results of the phase III CARTITUDE-4 study were also announced, as well as data showing the sustained remission rates in different subgroups and real-world research results of CARVYKTI through six poster presentations. Legend also presented the first-in-human trial data of the dual-target homologous allogeneic CAR-T candidate product LUCAR-G39D at the ASH Annual Meeting through an oral presentation.